Ravulizumab (Ultomiris®) accepted for restricted use within NHSScotland
This is recommended under advice of national renal complement therapeutics service for treatment of patients with body weight ≥10kg with atypical haemolytic uremic syndrome who are complement inhibitor treatment-naïve or have received eculizumab for ≥3 months and responded to it.
Source:
Scottish Medicines Consortium